Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Glehnia littoralis* is a perennial medicinal herb native to the coastal regions of East Asia, traditionally utilized in Chinese medicine (as "Beishashen") to nourish Yin, clear the lungs, and promote the generation of body fluids. The plant's roots contain a diverse array of bioactive constituents, including polysaccharides (GLPs), furanocoumarins (such as imperatorin, phellopterin, and bergapten), and polyacetylenes (falcarinol and falcarindiol). Pharmacological research has demonstrated that *Glehnia littoralis* exerts multi-target therapeutic effects, including anti-inflammatory, anti-allergic, hypoglycemic, immunomodulatory, and anti-cancer activities. Its mechanisms of action involve the stabilization of mast cells, inhibition of N-acylethanolamine acid amidase (NAAA), activation of the aryl hydrocarbon receptor (AhR) via gut microbiota modulation, and upregulation of the PPAR signaling axis. It is currently being investigated in preclinical models for various conditions, including allergic airway inflammation, ulcerative colitis, periodontitis, and metabolic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glehnia littoralis.